Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Nephrology
Volume 2014, Article ID 308729, 4 pages
http://dx.doi.org/10.1155/2014/308729
Case Report

Successful Antiviral Triple Therapy in a Longstanding Refractory Hepatitis C Virus Infection with an Acute Kidney Injury

1Department of Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Auerbach Street 110, 70179 Stuttgart, Germany
2Department of Pathology, Erlangen University Hospital, Krankenhaus Street 8-10, 91054 Erlangen, Germany

Received 28 March 2014; Accepted 4 August 2014; Published 14 August 2014

Academic Editor: Ichiei Narita

Copyright © 2014 David Callau Monje et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Cacoub, C. Renou, E. Rosenthal et al., “Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C,” Medicine, vol. 79, no. 1, pp. 47–56, 2000. View at Google Scholar
  2. F. Lunel, L. Musset, P. Cacoub et al., “Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage,” Gastroenterology, vol. 106, no. 5, pp. 1291–1300, 1994. View at Google Scholar · View at Scopus
  3. F. Poordad, J. McCone Jr., B. R. Bacon et al., “Boceprevir for untreated chronic HCV genotype 1 infection,” The New England Journal of Medicine, vol. 364, no. 13, pp. 1195–1206, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. B. R. Bacon, S. C. Gordon, E. Lawitz et al., “Boceprevir for previously treated chronic HCV genotype 1 infection,” The New England Journal of Medicine, vol. 364, no. 13, pp. 1207–1217, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Covic, D. Abramowicz, A. Bruchfeld et al., “Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement,” Nephrology Dialysis Transplantation, vol. 24, no. 3, pp. 719–727, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Sarrazin, T. Berg, R. S. Ross et al., “Prophylaxis, diagnosis and therapy of Hepatitis C Virus (HCV) infection: the German guidelines on the management of HCV infection,” Zeitschrift fur Gastroenterologie, vol. 48, no. 2, pp. 289–351, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. C. H. Liu, C. F. Huang, C. J. Liu et al., “Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial,” Annals of Internal Medicine, vol. 159, no. 11, pp. 729–738, 2013. View at Publisher · View at Google Scholar
  8. D. Saadoun, M. Resche Rigon, V. Thibault et al., “Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24,” Annals of the Rheumatic Diseases, vol. 73, no. 5, pp. 831–837, 2014. View at Publisher · View at Google Scholar
  9. L. Alric, E. Plaisier, S. Thébault et al., “Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN,” American Journal of Kidney Diseases, vol. 43, no. 4, pp. 617–623, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Sarrazin, T. Berg, M. Cornberg et al., “Expert opinion on Boceprevir- and Telaprevir-based triple therapies of chronic hepatitis C,” Zeitschrift fur Gastroenterologie, vol. 50, no. 1, pp. 57–72, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Fabrizi, A. Aghemo, and P. Messa, “Hepatitis C treatment in patients with kidney disease,” Kidney International, vol. 84, pp. 874–879, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Casanovas-Taltavull, C. Baliellas, M. Llobet et al., “Preliminary results of treatment with pegylated interferon alpha 2A for chronic hepatitis C virus in kidney transplant candidates on hemodialysis,” Transplantation Proceedings, vol. 39, no. 7, pp. 2125–2127, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. M. W. Russo, R. Ghalib, S. Sigal, and V. Joshi, “Randomized trial of pegylated interferon α-2b monotherapy in haemodialysis patients with chronic hepatitis C,” Nephrology Dialysis Transplantation, vol. 21, no. 2, pp. 437–443, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Bruchfeld, K. Lindahl, O. Reichard, T. Carlsson, and R. Schvarcz, “Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients,” Journal of Viral Hepatitis, vol. 13, no. 5, pp. 316–321, 2006. View at Publisher · View at Google Scholar · View at Scopus